Laith Mohammad Hilal Al-Shdifat

Dr. Laith Mohammad Hilal Al-Shdifat

Applied Science Private University, Amman, Al ‘Āşimah, Jordan
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Nanomaterials
Verified
Journal Article
Open access
PDF file
NBNorfarina Bahari
Norfarina Bahari
NHNorhashila Hashim
Norhashila Hashim
Khalina AbdanKhalina Abdan
Khalina Abdan
AAAbdah Md Akim
Abdah Md Akim
BMBernard Maringgal
Bernard Maringgal
Laith Mohammad Hilal Al-ShdifatLaith Mohammad Hilal Al-Shdifat
Laith Mohammad Hilal Al-Shdifat
The use of natural reducing and capping agents has gained importance as a way to synthesize nanoparticles (NPs) in an environmentally sustainable manner. Increasing numbers of studies have been published on the green synthesis of NPs using natural sources such as bacteria, fungi, and plants. In recent years, the use of honey in the synthesis of metal and metal oxide NPs has become a new and promising area of research. Honey acts as both a stabilizing and reducing agent in the NP synthesis process and serves as a precursor. This review focuses on the use of honey in the synthesis of silver NPs (Ag-NPs) and zinc oxide NPs (ZnO-NPs), emphasizing its role as a reducing and capping agent. Additionally, a comprehensive examination of the bio-based reducing and capping/stabilizing agents used in the honey-mediated biosynthesis mechanism is provided. Finally, the review looks forward to environmentally friendly methods for NP synthesis.

Verified
Journal Article
Open access
PDF file
AAAhmad R. Alsayed
Ahmad R. Alsayed
AAAnas Abed
Anas Abed
HKHeba Khader
Heba Khader
Laith Mohammad Hilal Al-ShdifatLaith Mohammad Hilal Al-Shdifat
Laith Mohammad Hilal Al-Shdifat
LHLuai Hason
Luai Hason
MZMalek Zihlif
Malek Zihlif
The wide diversity of microbiota at the genera and species levels across sites and individuals is related to various causes and the observed differences between individuals. Efforts are underway to further understand and characterize the human-associated microbiota and its microbiome. Using 16S rDNA as a genetic marker for bacterial identification improved the detection and profiling of qualitative and quantitative changes within a bacterial population. In this light, this review provides a comprehensive overview of the basic concepts and clinical applications of the respiratory microbiome, alongside an in-depth explanation of the molecular targets and the potential relationship between the respiratory microbiome and respiratory disease pathogenesis. The paucity of robust evidence supporting the correlation between the respiratory microbiome and disease pathogenesis is currently the main challenge for not considering the microbiome as a novel druggable target for therapeutic intervention. Therefore, further studies are needed, especially prospective studies, to identify other drivers of microbiome diversity and to better understand the changes in the lung microbiome along with the potential association with disease and medications. Thus, finding a therapeutic target and unfolding its clinical significance would be crucial.

18 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HLHsuan-Yu J. Lin
Hsuan-Yu J. Lin
RBRachana Rao Battaje
Rachana Rao Battaje
JTJinlong Tan
Jinlong Tan
MDMunikumar Doddareddy
Munikumar Doddareddy
HDHemendra Pal Singh Dhaked
Hemendra Pal Singh Dhaked
Paul GroundwaterPaul Groundwater
Paul Groundwater
Multi-drug resistance is increasing in the pathogenic bacterium S. pneumoniae, which is mainly responsible for meningitis and community-acquired pneumonia (CAP), highlighting the need for new anti-pneumococcal agents. We have identified a potential anti-pneumococcal agent, enol 3, which acts by hindering the cell division process by perturbing Z-ring dynamics inside the cell. Enol 3 was also shown to inhibit FtsZ polymerization and induce its aggregation in vitro but does not affect the activity of tubulin and alkaline phosphatase. Docking studies show that 3 binds near the T7 loop, which is the catalytic site of FtsZ. Similar effects on Z-ring and FtsZ assembly were observed in B. subtilis, indicating that 3 could be a broad-spectrum anti-bacterial agent useful in targeting Gram-positive bacteria. In conclusion, compound 3 shows strong anti-pneumococcal activity, prompting further pre-clinical studies to explore its potential.